Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings - Connecticut, July 2022.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
22 Sep 2023
Historique:
medline: 25 9 2023
pubmed: 21 9 2023
entrez: 21 9 2023
Statut: epublish

Résumé

Two siblings aged 5 and 15 years from Connecticut were hospitalized with petechial rash, oral mucositis, and severe thrombocytopenia approximately 10 days after they played with a jar of elemental mercury they found in their home. Before the mercury exposure was disclosed, the siblings were treated with platelet transfusions, intravenous immune globulin (IVIG) for possible immune thrombocytopenic purpura, and antibiotics for possible infectious causes. When their conditions did not improve after 6 days, poison control facilitated further questioning about toxic exposures including mercury, testing for mercury, and chelation with dimercaptosuccinic acid. The older sibling soon recovered, but the younger child required a prolonged hospitalization for severe thrombocytopenia, ultimately receiving repeated doses of IVIG, steroids, and romiplostim, a thrombopoietin receptor agonist. Close collaboration among multiple agencies was required to identify the extent of mercury contamination, evaluate and treat the other family members, and decontaminate the home. These cases demonstrate the importance of ongoing public health outreach to promote early detection of elemental mercury toxicity, and the need to evaluate for environmental exposures when multiple close contacts experience similar signs and symptoms.

Identifiants

pubmed: 37733629
doi: 10.15585/mmwr.mm7238a2
pmc: PMC10519713
doi:

Substances chimiques

Immunoglobulins, Intravenous 0
Mercury FXS1BY2PGL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1031

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

J Toxicol Clin Toxicol. 1995;33(5):449-55
pubmed: 7650769
Inhal Toxicol. 2012 Aug;24(10):652-8
pubmed: 22906171
Am J Emerg Med. 1992 May;10(3):258-61
pubmed: 1316757
Cad Saude Publica. 2019 Feb 11;35(2):e00091618
pubmed: 30758455
J Med Toxicol. 2020 Oct;16(4):470-476
pubmed: 32572678

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH